OTCMKTS:OPHLF Ono Pharmaceutical Q2 2026 Earnings Results & Report $14.90 0.00 (0.00%) As of 11/11/2026 Ono Pharmaceutical beat analyst expectations on both earnings and revenue in its Q2 2026 results, released October 30, 2025. The company reported EPS of $0.3225 versus the $0.2748 consensus estimate, while revenue of $876.10 million topped the $790.87 million estimate by $85.23 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateOctober 30, 2025TimeBefore Market Opens Ono Pharmaceutical EPS ResultsActual EPS$0.3225Consensus EPS $0.2748Beat/MissBeat by +$0.0477One Year Ago EPSN/AEPS Beat Rate3 of last 5 quartersOno Pharmaceutical Revenue ResultsActual Revenue$876.10 millionExpected Revenue$790.87 millionBeat/MissBeat by +$85.23 millionYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Ono Pharmaceutical Q2 2026 Earnings FAQ Did Ono Pharmaceutical beat earnings estimates for Q2 2026? Ono Pharmaceutical (OTCMKTS:OPHLF) reported earnings of $0.3225 per share for Q2 2026, beating the consensus estimate of $0.2748. The report was announced on Thursday, October 30, 2025. What was Ono Pharmaceutical's revenue for Q2 2026? Ono Pharmaceutical reported revenue of $876.10 million for Q2 2026, against a consensus estimate of $790.87 million. Ono Pharmaceutical Earnings HeadlinesHead-To-Head Survey: Ovid Therapeutics (NASDAQ:OVID) vs. Ono Pharmaceutical (OTCMKTS:OPHLF)November 6, 2026 | americanbankingnews.comOno Pharmaceutical Co. Ltd. H1 Profit RisesOctober 29, 2026 | rttnews.comWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.November 12 at 1:00 AM | Base Camp Trading (Ad)Ono Pharma Announces Results From Five Phase 2 Clinical Studies of ONO-1110, an Endocannabinoid ModulatorOctober 28, 2026 | businesswire.comBiohaven licenses IgG degrader portfolio to Japan’s OnoOctober 8, 2026 | seekingalpha.comOno’s New Pediatric Cancer Trial Signals Steady Pipeline Progress for O.P.H.L.F InvestorsOctober 6, 2026 | tipranks.comSee More Ono Pharmaceutical Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Ono Pharmaceutical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ono Pharmaceutical and other key companies, straight to your email. Email Address About Ono PharmaceuticalOno Pharmaceutical (OTCMKTS:OPHLF) Co., Ltd. is a Japan-based research-driven pharmaceutical company that discovers, develops, manufactures and markets prescription medicines. Founded in 1717 as a medicine wholesaler, the company is headquartered in Osaka. Ono’s research and product portfolio spans areas including oncology, immunology, neurology and diabetes. A notable product is Opdivo (nivolumab), an immuno-oncology medicine developed through a collaboration involving Ono and Medarex, which was later acquired by Bristol Myers Squibb. The company serves patients in Japan and works with international pharmaceutical partners to develop and commercialize medicines in other markets.View Ono Pharmaceutical ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-OffKeeping AI Cool: AAON Rides the AI Heatwave to Record GrowthPalantir’s Real Washington Risk Isn’t the Budget—It’s OversightCan Constellation Energy's Contracts Power a Stock Rebound?IonQ Raised the Bar, But 3 Quantum Rivals Face Tough QuestionsAmazon's Rally Is Outpacing Big Tech, But Can AWS Justify the AI Spending?Aehr Test Systems Notches Another Post-Earnings Win as Sales Triple on AI Demand Upcoming Earnings Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
